Aegle’s capital raise will fund the first clinical trial in the U.S. using exosomes isolated from allogeneic mesenchymal stem cells as therapy. Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal ...
Read More »ReNeuron Publishes Exosome Nanomedicine Platform Data
LONDON (Alliance News) – Stem-cell therapy development company ReNeuron Group PLC Tuesday said data related to its exosome nanomedicine platform has been published in peer-reviewed scientific journal PLOS ONE. The UK-based company is researching the “therapeutic potential of exosomes derived ...
Read More »ReNeuron’s frozen CTX cell product potentially a “major competitive advantage”
from proactiveinvestors Australia by John Harrington Cash-rich stem cell therapy development company ReNeuron (LON:RENE) is starting to press harder on the accelerator with some of its programmes. The firm’s interim results, covering the six months to end-September, were largely about recapping the ...
Read More »